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ABSTRACT
Objectives: Minimally invasive gynaecological surgeries are performed for several malignant and nonmalignant indica-
tions. The aim of our study was to evaluate the rate of unexpected malignancies among women who underwent laparo-
scopical supracervical hysterectomy (LASH) with power morcellation. 
Material and methods: The retrospective analysis included clinical data of 426 consecutive female patients who under-
went LASH with power morcellation due to presumed benign disorders (78.4% — symptomatic uterine fibromas, 12.7% 
— abnormal uterine bleeding, 8.9% — suspicion of uterine adenomyosis) between January 2011 and December 2015. Pre-
malignant or malignant preoperative abnormalities in the cervix and the uterine corpus were contraindications for LASH.
Results: The unexpected malignancies were found in four patients from study group: one ovarian cancer located on the 
inner part of simple ovarian cyst and 3 endometrial carcinomas (0.9%) were documented. All these patients underwent 
abdominal reoperations and no histological abnormalities were detected in the extirpated cervix and adnexa.
Conclusions: The incidence of unintended endometrial carcinoma in morcellated uterus after LASH was relatively small. 
However, careful pre-operative counseling should be undertaken in order to exclude the possibility of any malignant disease 
in uteri among women scheduled to power morcellation.
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INTRODUCTION
In current gynecological practice, hysterectomy be-
longs to the standard procedures for several malignant and 
nonmalignant indications and is one of the most commonly 
performed surgeries [1–3]. However, with technological 
progress in the 21st century, total abdominal hysterectomy 
as a primary intervention for benign indications belongs 
to the past. Supracervical hysterectomy, as less invasive, 
is an alternative to total hysterectomy for benign uterine 
disorders, however the American College of Obstetricians 
and Gynecologists (ACOG) does not recommend this proce-
dure as superior to total hysterectomy [4]. With appropriate 
preoperative consulting, even large uteri can be surgically 
removed with laparoscopic assistance either transvagi-
nally or totally laparoscopically. Of course, even today the 
majority of malignant diseases of the cervix, uterus, tubes 
or ovaries are still primary indications for open abdominal 
surgery; however, the number of centres which are able 
to safely use advanced laparoscopic techniques for ma-
lignant disease of the cervix and uterus is growing. Since 
1989, when first laparoscopic hysterectomy was performed, 
the laparoscopic supracervical approach to hysterectomy 
(LASH) has become very popular both in Europe and the 
United States [5, 6].
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However, in 2014, the Food and Drug Administration 
(FDA), due to safety concerns, namely the possibility for 
intraperitoneal dissemination of occult uterine malignan-
cies that may occur via morcellation during hysterectomy 
and myomectomy, issued a statement that the power 
morcellation should be contra-indicated in “the majority 
of women” due to the potential risk of spreading occult 
uterine sarcoma [7]. This was partially in agreement with 
a previously published statement by the American Asso-
ciation of Gynecologic Laparoscopists that in the case of 
known or suspected uterine malignancy, morcellation is 
contraindicated [8]. Of course, the difference between these 
two statements is obvious and critically important for gen-
eral clinical practice because, according to FDA statement, 
gynecological surgeons should abandon all procedures 
(except total abdominal hysterectomy) commonly used for 
the surgical treatment of symptomatic leiomyomas keeping 
in mind that occasionally a small risk of spreading occult 
cancer exists. These procedures include: vaginal hyster-
ectomy (scalpel morcellation very often used to decrease 
the size of uterus), mini-laparotomy hysterectomy (scalpel 
morcellation often necessary), laparoscopic hysterectomy 
(scalpel morcellation), laparoscopic supra-cervical hyster-
ectomy (cervix cut-through and power or scalpel morcel-
lation obligatory), open supracervical hysterectomy (cervix 
cut-through), laparoscopic myomectomy (power or scalpel 
morcellation obligatory), mini-laparotomy myomectomy 
(scalpel morcellation very often necessary), hysteroscopic 
myomectomy (intrauterine morcellation obligatory), uterine 
artery embolization (no specimen and no histopathological 
diagnosis with possibility of delayed optimal treatment in 
the case of unexpected malignancy), high-intensity focused 
ultrasound (no specimen and no histopathological diag-
nosis with possibility of delayed treatment in the case of 
malignancy). Therefore the pivotal question is how often 
can we really expect occult malignancy when the power 
morcellation is used during supracervical hysterectomy 
performed due to potentially benign indications.
OBJECTIVES
The aim of our study was to evaluate the rate of un-
expected malignancies among women who underwent 
supracervical laparoscopic hysterectomy with power mor-
cellation due to presumed benign conditions.
MATERIAL AND METHODS
The study protocol was approved by the local institu-
tional ethical committee. Between January 2011 and De-
cember 2015 — 426 LASH procedures were performed 
due to presumed benign indications (Table 1). In this retro-
spective study we evaluated all cases of unexpected occult 
malignancies in patients after LASH. Main indications for 
LASH were the symptomatic uterine myomas or dysfunc-
tional uterine bleeding resistant to conservative therapy. 
All patients were preoperatively vaginally examined in-
cluding a speculum visualization of the cervix and vaginal 
sonography was also performed. In the case of sonographic 
endometrial abnormalities, a diagnostic endometrial aspi-
ration biopsy or dilatation and curettage were performed 
before surgery. A cervical PAP test, performed within 1 year 
before surgery, was available for every patient. Premalignant 
or malignant preoperative findings in the cervix and the 
uterine corpus were considered as contraindications for 
LASH. Standardized LASH operation technique with electric 
power morcellation was used in order to remove the uter-
ine corpus [9]. We also routinely removed both oviducts in 
order to reduce the probability of ovarian functional cysts 
and future malignancy [10]. All tissue specimens were fixed 
in 10% buffered formalin for at least 24 hours and sent to 
the Department of Clinical Pathomorphology. The speci-
mens were counted, measured and grossly examined before 
and after sectioning for identification of basic anatomical 
structures and pathological lesions. Then, specimens were 
sampled according to the following protocol, i.e. (a) 1–2 sam-
ples from intact smaller fibromas or at least one sample 
from each fragment of morcelled fibromas, especially from 
abnormally looking areas, (b) one from grossly unaffected 
myometrium or 2–3 in the case of macroscopic suspicion of 
adenomyosis and (c) 1–2 from grossly normal endometrium 
in the case of no clinical suspicion of endometrial pathology, 
at least 2–3 samples including one through entire uterine 
wall (if possible) in grossly visible endometrial tumours or 
the whole endometrium in the suspicion of hyperplasia. 
Furthermore, three samples from each fallopian tube and 
Table 1. Indications for laparoscopical supracervical hysterectomy (LASH) and number of the past five years
Indications for surgery 2011 (n = 8)
2012 
(n = 31)
2013 
(n = 146)
2014 
(n = 117)
2015 
(n = 124)
Total
2011–2015 
(n = 426)
Uterine fibroids 5 26 111 93 99 334
Adenomyosis 2 3 14 8 11 38
Abnormal uterine bleeding 1 2 21 16 14 54
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1–2 from each ovary when they were provided. Generally, 
the number of samples depended on initial clinical diagnosis 
and gross examination of each particular case. All samples 
were routinely processed to the paraffin blocks, sectioned 
and stained using haematoxylin and eosin and then micro-
scopically examined.
RESULTS
Patients’ data from 426 LASH operations with electric 
power morcellation were evaluated. The indications for 
surgery in 334 patients (78.4%) were symptomatic uterine 
fibromas, in 54 patients (12.7%) abnormal uterine bleeding, 
in 38 patients (8.9%) suspicion of uterine adenomyosis. One 
case of intra-operative complication (small bowel laceration) 
was caused by use of the morcellator. In total, four unexpected 
malignancies were found among patients from the study 
group: one ovarian cancer located on the inner part of simple 
ovarian cyst (in that case adnexectomy was performed before 
LASH and adnexa were removed in an endobag), and 3 endo-
metrial carcinomas (0.9%). All these patients underwent open 
reoperations and no histological abnormalities were detected 
in the extirpated cervix and adnexa (Table 2). 
DISCUSSION
When surgery for presumed benign fibroids is per-
formed there is always a big concern regarding the risk of 
occult leiomyosarcomas (LMS) found later in a histopatho-
logical specimen. The presented data show a rather low 
uterine malignancy rate in patients undergoing LASH. In 
fact, in our study group, we did not find any of the most ag-
gressive tumours (stromal sarcoma or leiomyosarcoma) with 
a really bad prognosis. On the other hand, FDA estimated 
that for every 458 women having surgery for fibroids, one 
woman would be found to have an occult leiomyosarcoma, 
and this risk even increase to 1 in 352 for any sarcoma [7]. 
Fortunately, this was not found in our material, but it should 
be mentioned that in our study population, ultrasound find-
ings of a large irregular vascular mass, with anechoic (cystic) 
areas reflecting necrosis within myomas where contraindica-
tion to LASH existed, because such pictures are suspicious 
for LMS. Recently, at least two big studies also challenged 
the FDA statement concerning the presumed risk of oc-
cult uterine malignancy during LASH operation. Pritts et al. 
published a meta-analysis of 133 studies and determined 
that the prevalence of LMS among 30,193 women having 
surgery for presumed benign fibroids was 1 in 1.960, or 
0.051% (95% CI: 0.16–0.98) or approximately 1 in 2.000 op-
erations [11]. Also, Bojahr et al. reported a very low rate of 
LMS among 10,731 women who underwent a laparoscopic 
supracervical hysterectomy mainly due to symptomatic 
uterine myomas with subsequent electric power morcel-
lation between 1998–2014 [12]. In such big cohorts, the 
authors reported 6 sarcomas (0.06%), including 4 endome-
trial stromal sarcomas (0.04%), 2 leiomyosarcomas (0.02%), 
and 8 endometrial cancers (0.07%). This yielded a relatively 
low total uterine malignancy rate of 0.13%. Moreover, dur-
ing median follow-up of 65.6 months (13–169 months), no 
recurrence was reported in any patients with endometrial 
cancer and 5 out of 6 sarcoma patients. Only one patient 
diagnosed with leiomyosarcoma died 13 months after LASH 
due to peritoneal and bone metastases. Obviously, due to 
the rarity of these malignancies the data on the prevalence 
of sarcoma in morcellated specimens are limited and even 
fewer studies have focused on the real influence of power 
morcellation on the survival rate in patients who underwent 
such an unintentional procedure during primary surgery 
[13–15]. In another analysis of re-operation rates after LASH, 
it was found that extirpations of the cervical stump were 
performed in 2 women (0.66%) due to leiomyosarcomas in 
the morcellated uterus [16].
Table 2. Histopathological findings after laparoscopical supracervical hysterectomy (LASH) and after second-look laparotomy
Patient data Histopathological report after LASH Histopathological report after second-look laparotomy (remnant of the uterus or other localization of pathology)
Patient 1. (57 yrs) Endometrial adenocarcinoma G1 limited to the endometrium
Simple endometrial hyperplasia and in part complex endometrial 
hyperplasia with atypia
Chronic cervicitis
Normal ovaries
Patient 2. (53 yrs) Endometrial adenocarcinoma G1 in situ
Proliferative endometrium and in part secretory endometrium
Chronic cervicitis
Normal ovaries
Patient 3. (57 yrs) Endometrial adenocarcinoma G1
Proliferative endometrium in part leiomyoma
Chronic cervicitis
Normal ovaries
Patient 4. (54 yrs) Clarocellulare ovarian cystadenocarcinoma
Peritoneum from the left side of diaphragm- small amount of dyskariotic 
cells probably neoplastic
Normal ovaries
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Pritts and co-workers challenged the question whether 
morcellation of occult leiomyosarcomas resulted in inferior 
outcomes, compared with en bloc tumour removal dur-
ing an open classical surgery. The authors concluded that 
there is no reliable evidence that morcellation, power or 
manual, substantially results in upstaging of the disease 
[17]. Based on current literature, it seems a100% certainty 
that before an operation we can exclude the possibility of 
the occurrence of occult malignancy being almost unattain-
able, but of course, every effort should be undertaken to 
achieve this goal. The main challenge with triaging patients 
to the appropriate minimally invasive surgery (LASH with 
power morcellation) or classical open surgery is identifying 
patients with uterine sarcomas and endometrial carcino-
mas. This could be achieved using various imaging tech-
niques, endometrial sampling, and performing a thorough 
physical examination during preoperative evaluation of 
patients with uterine and intrauterine masses. Of course, 
in order to exclude intrauterine malignancy, the best way 
is to obtain endometrial biopsy which should always be 
performed along with measurement of endometrial thick-
ness by trans-vaginal ultrasonography (TVU) in any case of 
abnormal uterine bleeding [18]. In the nested case-control 
study of postmenopausal women (over 48.000 participants) 
endometrial thickness and endometrial abnormalities were 
recorded. The analysis performed only in women with endo-
metrial cancer without postmenopausal bleeding and with 
a cutoff of 5 mm showed sensitivity of 77.1% and specificity 
of 85.8%. This study has proved the usage of trans-vaginal 
ultrasonography as a screening tool in postmenopausal 
women [19]. In a large retrospective meta-analysis it was 
found that the detection rate for endometrial carcinoma 
with endometrial biopsy was 99.6% in postmenopausal and 
91% in premenopausal women [20]. The good (but of course 
not ideal) correlation between preoperative endometrial 
sampling and postoperative histology was also proved for 
the endometrioid histology subtype. Unfortunately, such 
a correlation was observed only in 40% for sarcomas. The 
sensitivities of pre-operative curettage and pipelle biopsy 
for identifying endometrioid and non-endometrioid can-
cers were 96.5% and 86.5%, respectively [21]. One of the 
most common challenges during the endometrial sam-
pling procedure is to obtain a good quality and sufficient 
tissue sample. In the large retrospective study, histological 
findings were analyzed in 17.552 samples collected dur-
ing endometrial curettage (EMC) and endometrial biopsy 
(EMB). There was no statistical difference between sam-
ples reported as non-diagnostic between EMB (6.4%) and 
EMC (6.5%) groups. Repeat sample collection procedures 
were performed in 38% of patients with non-diagnostic 
results of initial biopsy. Malignant findings were described 
in 5% of them; moreover, one-fourth of repeated biopsies 
were still insufficient. Seven percent of patients with initial 
non-diagnostic specimens had undergone hysterectomy 
and in 35% postoperative histopathological reports revealed 
the uterine malignancy. The authors underlined that com-
ments of pathologists, especially if any abnormal findings 
in non-diagnostic specimen were observed, may help in 
further repeated diagnosis and management. In this study, 
any abnormal histologic findings in initial, non-diagnostic 
endometrial sample were associated with uterine ma-
lignancy in 43% of patients [22]. In another prospective 
multicenter study the endometrial sampling in 29.8% was 
non-diagnostic due to an insufficient amount of endome-
trial tissue. In over one-fifth of patients with technically 
failed samples the endometrial malignancy was diagnosed. 
In six patients (7.1%) from the group with an insufficient 
sample amount the endometrial cancer was observed. The 
risk factor for technical failure was associated with nullipar-
ity, and also the advanced age of the patients increased the 
risk of an insufficient sample [23]. An even bigger clinical 
problem with proper preoperative diagnosis is commonly 
encountered with uterine sarcomas and leiomyosarcomas, 
mainly because of the distribution of these lesions within 
the myometrium. The reported sensitivities of dilatation and 
curettage within 33–67% are far from ideal [24, 25]. Currently 
available clinical data clearly indicate that rapid enlarge-
ment of the uterus, which traditionally was considered as 
a characteristic of presumed malignancy is not a reliable 
predictor associated with sarcoma, but on the other hand, 
a stable size of presumed fibroids during several months of 
observation make a sarcoma highly unlikely [26, 27].
In current gynecological practice, ultrasonography due 
to its sensitivity, accessibility, and relatively low cost is the 
first line imaging technique when evaluating patients with 
uterine abnormalities before operation. However, in cases 
of mesenchymal malignant tumours sonographical scan-
ning is much less reliable even if sarcomas presents certain 
features such as mixed echogenic parts, central necrosis, 
and irregular vasculature on Doppler evaluation [28, 29].
Also, magnetic resonance imaging (MRI) is not 100% reli-
able in the diagnosis of mesenchymal tumours. It has been 
shown that high signal intensity and ill-defined margins are 
very often encountered, but neither is a reliable indicator 
of malignancy [30, 31].
Recently, the European Society of Gynaecological En-
doscopy published an official statement and practical rec-
ommendations on fibroid morcellation based on the cur-
rent level of available evidence. According to the authors, 
the currently available level of evidence is not sufficient 
to give exact recommendations; however, they presented 
a flowchart to offer a structure in the clinical management. 
In the case of patients scheduled for electric power morcel-
lation tissue necrosis and high vascularity visible on TVU 
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are contraindications for this procedure. If tissue necrosis 
and high vascularization is not present and the patient 
is < 40 years, morcellation is not contraindicated, but in 
patients > 40 years old additional safety reassurance should 
be performed, taking into account menopausal status, pres-
ence of abnormal uterine bleeding, elevated lactate dehy-
drogenase level and the size of the largest fibroid > 8 cm [32].
Correct histopathological diagnosis of specimens after 
morcellation requires evaluation of multiple samples, pre-
ceded by careful macroscopic examination by an experi-
enced, observant pathologist. Since specimens are usually 
largely fragmented, deformed and especially after power 
morcellation, partly thermally damaged, gross evaluation 
is difficult and may lead to inadequate sampling. Therefore, 
false negative results of microscopic examination may be 
the consequence of missing an important tissue piece at 
sectioning or too low a number of samples, especially in some 
mesenchymal origin tumours (leiomyoma variants, uterine 
smooth muscle tumour of uncertain malignant potential 
— STUMP), or in small or superficial endometrial carcinomas, 
especially growing in polyps or in endometrium deformed by 
big leiomyomas. Small numbers of samples taken for techni-
cal reasons form suspected uterine tumours or lower quality 
of sections compared to routinely processed samples, may 
also be the source of mistakes in frozen sections examination. 
Moreover, during morcellation, most of the anatomic features 
can be completely destroyed. All those factors can decrease 
the accuracy of pathological diagnosis [33].
CONCLUSIONS
Although the incidence of unintended endometrial 
carcinoma in morcellated uterus after LASH is relatively 
small, such possibility definitely exists. Therefore, careful 
pre-operative counseling should be undertaken in order to 
exclude the possibility of a malignant disease (namely leio-
myosarcoma and endometrial carcinoma) among patients 
scheduled for power morcellation after supracervical lapa-
roscopic hysterectomy. A diagnostic endometrial aspiration 
biopsy or dilatation and curettage should be considered in 
all patients qualified for LASH. Only such a clinical attitude 
accompanied by patients’ informed consent will guarantee 
the best choice of safe treatment tailored to an individual 
situation.
Conflict of interest
This study was not supported by any pharmaceutical 
company.
REFERENCES
1. Mettler L, Sammur W, Schollmeyer T. Clinical medicine insights. Repro-
ductive Health. 2010, 4, 7–22.
2. Forsgren C, Altman D. Long-term effects of hysterectomy. A focus on 
the aging patient. Aging Health. 2013, 9, 179–187.
3. Lefebvre G, Allaire C, Jeffrey J, [et al.]. SOGC clinical guidelines. Hyster-
ectomy. J Obstet Gynaecol Can. 2002, 24, 37–61.
4. ACOG committee opinion no. 444: Choosing the route of hysterectomy 
for benign disease. Obstet Gynecol. 2009, 114, 1156–1158.
5. Donnez O, Jadoul P, Squifet J, [et al.]. A series of 3190 laparoscopic 
hysterectomies for benign disease from 1990 to 2006: evaluation of 
complications compared with vaginal and abdominal procedures. BJOG. 
2008, 116, 492–500.
6. Learman LA, Summit RL Jr, Varner RE, [et al.]. A randomized comparison of 
total or supracervical hysterectomy: surgical complications and clinical 
outcomes. Obstet Gynecol. 2003, 102, 453–462.
7. U.S. Food and Drug Administration (2014) Laparoscopic Uterine Power 
Morcellation in Hysterectomy and Myomectomy: FDA Safety Com-
munication: http://www.fda.gov/MedicalDevices/ Safety/Alertsand 
Notices/ucm393576.htm.
8. AAGL Advancing Minimally Invasive Gynecology Worldwide AAGL posi-
tion statement: route of hysterectomy to treat benign uterine disease. 
J Minim Invasive Gynecol. 2011, 18, 1–3.
9. Bojahr B, Raatz D, Schonleber G, [et al.]. Perioperative complication 
rate in 1706 patients after a standardized laparoscopic supracervical 
hysterectomy technique. J Minim Invasive Gynecol. 2006, 13, 183–189.
10. McAlpine JN, Hanley GE, Woo MM, [et al.]. Opportunistic salpingectomy: 
uptake, risks, and complications of a regional initiative for ovarian cancer 
prevention. Ovarian Cancer Research Program of British Columbia. Am 
J Obstet Gynecol. 2014, 210, 471.e1–471.e11.
11. Pritts EA, Vanness DJ, Berek JS, [et al.]. The prevalence of occult leiomyo-
sarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gy-
necol Surg. 2015, 12, 165–177.
12. Bojahr B, De Wilde R, Tchartchian G. Malignancy rate of 10,731 uteri 
morcellated during laparoscopic supracervical hysterectomy (LASH). 
Arch Gynecol Obstet. 2015, 292, 665–672.
13. Seidman MA, Oduyebo T, Muto MG, Crum CP, Nucci MR, Quade BJ. Peri-
toneal dissemination complicating morcellation of uterine mesenchymal 
neoplasms. PLoS One. 2012, 7, e50058. 
14. Oduyebo T, Rauh-Hain AJ, Meserve EE, [et al.]. The value of re-exploration 
in patients with inadvertently morcellated uterine sarcoma. Gynecol 
Oncol. 2014, 132, 360–365.
15. Anupama R, Ahmad SZ, Kuriakose S, Vijaykumar DK, Pavithran K, 
Seethalekshmy NV. Disseminated peritoneal leiomyosarcomas after 
laparoscopic “myomectomy” and morcellation. J Minim Invasive Gynecol. 
2011, 18, 386–389.
16. Boosz A, Lermann J, Mehlhorn G, [et al.]. Comparison of re-operation 
rates and complication rates after total laparoscopic hysterectomy (TLH) 
and laparoscopy-assisted supracervical hysterectomy (LASH). Eur J Obstet 
Gynecol Reprod Biol. 2011, 158, 269–273.
17. Pritts EA, Parker WH, Brown J, [et al.]. The prevalence of occult leiomyo-
sarcoma after surgery for presumed uterine fibroids: a systematic review. 
J Minim Invasive Gynecol. 2015, 22, 26–33.
18. Timmermans A, Opmeer BC, Khan KS, [et al.]. Endometrial thickness 
measurement for detecting endometrial cancer in women with post-
menopausal bleeding: a systematic review and meta-analysis. Obstet 
Gynecol. 2010, 116, 160–167.
19. Jacobs I, Gentry-Maharaj A, Burnell M, [et al.]. Sensitivity of transvagi-
nal ultrasound screening for endometrial cancer in postmenopausal 
women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 
2011, 12, 38–48.
20. Dijkhuizen FP, Mol BW, Brölmann HA, [et al.]. The accuracy of endometrial 
sampling in the diagnosis of patients with endometrial carcinoma and 
hyperplasia: a meta-analysis. Cancer. 2000, 89 (8), 1765–1772.
21. Sany O, Singh K, Jha S. Correlation between preoperative endometrial 
sampling and final endometrial cancer histology. Eur J Gynaecol Oncol. 
2012, 33, 142–144.
22. Kandil D, Yang X, Stockl T, [et al.]. Clinical outcomes of patients with 
insufficient sample from endometrial biopsy or curettage. Int J Gynecol 
Pathol. 2014, 33, 500–506.
23. Visser NC, Breijer MC, Herman MC, [et al.]. Factors attributing to the failure 
of endometrial sampling in women with postmenopausal bleeding. Acta 
Obstet Gynecol Scand. 2013, 92, 1216–1222.
24. Leibsohn S, d’Ablaing G, Mishell DR, [et al.]. Leiomyosarcoma in a series 
of hysterectomies performed for presumed uterine leiomyomas. Am 
J Obstet Gynecol. 1990, 162, 968–976.
25. Bansal N, Herzog TJ, Burke W, [et al.]. The utility of preoperative endo-
metrial sampling for the detection of uterine sarcomas. Gynecol Oncol. 
2008, 110, 43–48.
551
Tomasz Rechberger et al., Laparoscopic supracervical hysterectomy and power morcellation
www. journals.viamedica.pl/ginekologia_polska
26. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for 
presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 
1994, 83, 414–418.
27. Baird DD, Garrett TA, Laughlin SK, [et al.]. Short-term change in growth 
of uterine leiomyoma: tumor growth spurts. Fertil Steril. 2011, 95, 
242–246.
28. Hata K, Hata T, Maruyama R, [et al.]. Uterine sarcoma: can it be differenti-
ated from uterine leiomyoma with Doppler ultrasonography? A prelimi-
nary report. Ultrasound Obstet Gynecol. 1997, 9, 101–104.
29.  Szabó I, Szánthó A, Csabay L, [et al.]. Color Doppler ultrasonography in 
the differentiation of uterine sarcomas from uterine leiomyomas. Eur 
J Gynaecol Oncol. 2002, 23, 29–34.
30. Schwartz LB, Zawin M, Carcangiu ML, [et al.]. Does pelvic magnetic 
resonance imaging differentiate among the histologic subtypes of 
uterine leiomyomata? Fertil Steril. 1998, 70, 580–587.
31. Tanaka YO, Nishida M, Tsunoda H, [et al.]. Smooth muscle tumors of 
uncertain malignant potential and leiomyosarcomas of the uterus: MR 
findings. J Magn Reson Imaging. 2004, 20, 998–1007.
32. Brölmann H, Tanos V, Grimbizis G, [et al.]. European Society of Gynaecologi-
cal Endoscopy (ESGE) steering committee on fibroid morcellation. Options 
on fibroid morcellation: a literature review. Gynecol Surg. 2015, 12, 3–15.
33. Hagemann IS, Hagemann AR, LiVolsi VA, [et al.]. Risk of occult malig-
nancy in morcellated hysterectomy: a case series. Int J Gynecol Pathol. 
2011, 30, 476–483.
